NCR Online Journal

The Cytokine Release Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cytokine Release Syndrome pipeline products will significantly revolutionize the Cytokine Release Syndrome market dynamics.

DelveInsight’s “Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Cytokine Release Syndrome, historical and forecasted epidemiology as well as the Cytokine Release Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Cytokine Release Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Get a Free sample for the Cytokine Release Syndrome Market Report –

https://www.delveinsight.com/report-store/cytokine-release-syndrome-market

Some of the key facts of the Cytokine Release Syndrome Market Report:

• The Cytokine Release Syndrome market size is projected to grow at a strong CAGR of 22% during the forecast period from 2026 to 2036.

• In March 2026, Emerging CAR-T Research: Preliminary findings from the Phase I CaMMouflage study of CB-011, an allogeneic BCMA-directed CAR-T cell therapy for multiple myeloma, demonstrated robust and sustained clinical responses alongside a favorable safety profile, highlighting continued progress toward enhancing treatment efficacy while minimizing the risk of Cytokine Release Syndrome (CRS).

• In February 2026, Phase III Trial Results: The Phase III OLYMPIA-3 trial assessing odronextamab in combination with CHOP for previously untreated diffuse large B-cell lymphoma demonstrated promising clinical efficacy. As bispecific antibodies advance into frontline treatment settings, monitoring and managing Cytokine Release Syndrome (CRS) continues to be a critical aspect of their safety profile.

• In December 2025, CytoAgents announced that preliminary safety data from its Phase I/II clinical trial would be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. CTO1681 was shown to be well tolerated at the 10μg three times a day (TID) dose.

• In December 2025, CytoAgents announced that data from two of its Investigational New Drug (IND) applications enabling studies will be presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025, in the UK. CTO1681 attenuates key cytokines known to drive CRS without compromising the CAR T-Cell-mediated tumor killing in vitro and in vivo.

• In April 2025, CytoAgents Inc., a clinical-stage biotech company developing CTO1681 for the prevention and treatment of Cytokine Release Syndrome (CRS), has announced the successful completion of the initial dose and dose-limiting toxicity observation period in its ongoing Phase 1b/2a trial. Based on the evaluation of safety and efficacy data, the Safety Review Committee (SRC) has approved advancing to the next higher planned dose in Cohort 2.

• The frequency and severity of CRS after CAR-T cell therapy vary between products; any grade 37–93%, grade 3 or 4 is around 1–23%.

• CRS occurs in approximately 43–100% of patients with leukemia or lymphoma receiving CAR-T cell therapy targeting CD19, with variability depending on the therapy and study population.

• The United States accounted for the highest incident cases of CRS, representing approximately 25% of total cases in the 7MM in 2025.

• Among the EU4 and the UK, Germany accounted for the highest incidence of CRS in 2025, followed by France, while Spain reported the lowest incidence.

• Key Cytokine Release Syndrome Companies: Genentech, Swedish Orphan Biovitrum (sobi), Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals, Fred Hutchinson Cancer Center, Ontario Clinical Oncology Group, GlaxoSmithKline, UNC Lineberger Comprehensive Cancer Center, SCRI Development Innovations and others

• Key Cytokine Release Syndrome Therapies: ACTEMRA/ROACTEMRA (tocilizumab), KINERET (anakinra), Itacitinib, Anakinra & Axicabtagene Ciloleucel, Defibrotide, Anakinra, Elranatamab injection, Otelixizumab, iC9-CAR19 cells, Teclistamab and others

Cytokine Release Syndrome Overview

Cytokine release syndrome (CRS) is a systemic inflammatory response that can occur as a result of certain medical treatments, particularly immunotherapies and cell-based therapies like CAR-T cell therapy. During these treatments, immune cells are activated and release large amounts of cytokines, which are signaling molecules that regulate the immune system. In CRS, this immune response becomes dysregulated, leading to an excessive release of cytokines into the bloodstream.

To Know in detail about the Cytokine Release Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cytokine Release Syndrome Market Insights

Cytokine Release Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cytokine Release Syndrome Epidemiology Segmentation:

The Cytokine Release Syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Incident Cases of Cytokine Release Syndrome

• Grade-specific Incident Cases of Cytokine Release Syndrome

• CRS Cases by CAR-T Therapies

• CRS Cases by Bispecific Antibodies

• CRS Cases by Allogeneic Transplant

• Total Treated Cases of Cytokine Release Syndrome

Download the report to understand which factors are driving Cytokine Release Syndrome epidemiology trends @ Cytokine Release Syndrome Epidemiological Insights

Cytokine Release Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cytokine Release Syndrome market or expected to get launched during the study period. The analysis covers Cytokine Release Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cytokine Release Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cytokine Release Syndrome Therapies and Key Companies

• Tocilizumab (ACTEMRA): Genentech

• CTO1681: CytoAgents

• ACTEMRA/ROACTEMRA (tocilizumab): Genentech

• KINERET (anakinra): Swedish Orphan Biovitrum (sobi)

• Itacitinib: Incyte

• Anakinra & Axicabtagene Ciloleucel: Kite, A Gilead Company

• Defibrotide: Jazz Pharmaceuticals

• Anakinra: Fred Hutchinson Cancer Center

• Elranatamab injection: Ontario Clinical Oncology Group

• Otelixizumab: GlaxoSmithKline

• iC9-CAR19 cells: UNC Lineberger Comprehensive Cancer Center

• Teclistamab: SCRI Development Innovations

To know more about Cytokine Release Syndrome treatment, visit @ Cytokine Release Syndrome Medications

Cytokine Release Syndrome Market Drivers

• Growing adoption of CAR-T cell therapies and bispecific antibodies is increasing the incidence of Cytokine Release Syndrome (CRS), driving demand for effective management and treatment options.

• Rising prevalence of hematologic malignancies and cancers treated with advanced immunotherapies is expanding the CRS patient pool.

• Advancements in immuno-oncology and cell-based therapies are creating opportunities for novel CRS prevention and treatment approaches.

• Increasing awareness and improved diagnosis of CRS among healthcare professionals are supporting earlier intervention and better patient outcomes.

Cytokine Release Syndrome Market Barriers

• Limited availability of approved CRS-specific therapies restricts treatment options and may hinder market expansion.

• High costs associated with CAR-T therapies and CRS management can limit patient access, particularly in cost-sensitive healthcare systems.

• Complexity in diagnosing and grading CRS severity may lead to variability in treatment approaches across healthcare settings.

• Potential safety concerns and adverse effects

Scope of the Cytokine Release Syndrome Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Cytokine Release Syndrome Companies: Genentech, Swedish Orphan Biovitrum (sobi), Incyte, Kite, A Gilead Company, Jazz Pharmaceuticals, Fred Hutchinson Cancer Center, Ontario Clinical Oncology Group, GlaxoSmithKline, UNC Lineberger Comprehensive Cancer Center, SCRI Development Innovations, and others

• Key Cytokine Release Syndrome Therapies: ACTEMRA/ROACTEMRA (tocilizumab), KINERET (anakinra), Itacitinib, Anakinra & Axicabtagene Ciloleucel, Defibrotide, Anakinra, Elranatamab injection, Otelixizumab, iC9-CAR19 cells, Teclistamab, and others

• Cytokine Release Syndrome Therapeutic Assessment: Cytokine Release Syndrome current marketed and Cytokine Release Syndrome emerging therapies

• Cytokine Release Syndrome Market Dynamics: Cytokine Release Syndrome market drivers and Cytokine Release Syndrome market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Cytokine Release Syndrome Unmet Needs, KOL’s views, Analyst’s views, Cytokine Release Syndrome Market Access and Reimbursement

Discover more about therapies set to grab major Cytokine Release Syndrome market share @ Cytokine Release Syndrome Treatment Landscape

Table of Contents

1. Cytokine Release Syndrome Market Report Introduction

2. Executive Summary for Cytokine Release Syndrome

3. SWOT analysis of Cytokine Release Syndrome

4. Cytokine Release Syndrome Patient Share (%) Overview at a Glance

5. Cytokine Release Syndrome Market Overview at a Glance

6. Cytokine Release Syndrome Disease Background and Overview

7. Cytokine Release Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Cytokine Release Syndrome

9. Cytokine Release Syndrome Current Treatment and Medical Practices

10. Cytokine Release Syndrome Unmet Needs

11. Cytokine Release Syndrome Emerging Therapies

12. Cytokine Release Syndrome Market Outlook

13. Country-Wise Cytokine Release Syndrome Market Analysis (2022–2036)

14. Cytokine Release Syndrome Market Access and Reimbursement of Therapies

15. Cytokine Release Syndrome Market Drivers

16. Cytokine Release Syndrome Market Barriers

17. Cytokine Release Syndrome Appendix

18. Cytokine Release Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/